Saxenda Clinical Trials

What Are Saxenda Clinical Trials?

Saxenda is a medication that is injectable and may be used for adults who suffer from excess weight problems. It is also possible for Saxenda to be utilized to treat type 2 diabetes as well as weight loss in specific patients. As a weight-loss supplement, Saxenda is intended to be used along with a reduced-calorie diet and an exercise regimen as prescribed by a doctor.

Saxenda is actually a trade name for this drug along with Victoza and a couple others. The correct way to refer to it is Liraglutide. It was legally approved for use in the United States in 2010 after already having been approved in Europe in 2009. As of 2019, doctors were prescribing more than 4 million individuals this medical supplement.

Why Is Saxenda Being Studied In Clinical Trials?

Researchers want to find out if Saxenda is safe and effective for treating obesity and facilitating weight loss in adults. Until recently, it had primarily been used in doing this for teenage people. The studies have focused on the more commonly known version of the drug, Liraglutide. If the results were positive, this could be a significant breakthrough for the medical industry.

How Does Saxenda Treatment Work?

It comes in a container shaped like a pen, and is an injectable substance. After the patient injects themselves with the Saxenda/Liraglutide, it takes about half an hour for it to take effect.

This supplement is designed to improve the control of blood glucose in people with Type 2 diabetes. As for treating obesity, the Liraglutide is successful when combined with a healthy diet plus exercise. All such practices must be overseen and prescribed by a doctor.

A Liraglutide usage summary for 2020 estimated that over 950,000 patients in the United States alone were given new prescriptions for this drug. It is ranked #146 on a list of popular drug prescriptions issued by doctors.

What Are Some Breakthrough Clinical Trials Involving Saxenda?

2015: Liraglutide and Weight Loss - this study was done in order to compare liraglutide to a placebo, and see if the effects were the same. The intent is that Liraglutide/Saxenda be utilized as a weight loss supplement, particularly in persons suffering with obesity.

Specifically, the researchers in the study wanted to see what the effects of a 3 mg dose of Liraglutide had as far as emptying the human stomach goes. The results of this pilot study were made public in late October 2017. It proved to be successful.

2023: Saxenda and Adult Weight Loss - researchers want to find out if Saxenda can be used to treat obesity in adult patients. This is a study that began on December 1, 2021, and ended on February 28, 2023. The results have not yet been made public.

Who Are the Key Opinion Leaders on Saxenda Clinical Trial Research?

Health Technology Assessment programme

D Shyangdan, E Cummins, P Royle, and N Waugh were the authors of an opinion-leading article encapsulated here. It was precisely about Liraglutide and its use for the treatment of Type 2 diabetes.